We enroll approximately 300 patients annually on NCI NCORP and pharmaceutical industry-sponsored clinical research trials. Our Precision Cancer Therapies Program concentrates on new drug development and Phase 1.
Fellows are expected to complete a clinical research project, perform a quality/performance improvement project, and publish case reports/literature reviews during their fellowship.
Funds are available for fellows to present their research at national meetings.
Current Fellow Research
COVID-19 in Relation to Hematological Events and Mortality in Subset of Inpatient Cancer Patients presented at AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020. (Dr. Gadde)
Outcomes of patients with multiple myeloma with COVID-19 infection presented at AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020. (Dr. Lunski)
Prostate cancer and COVID-19: Impact of hormonal therapy on severe outcomes presented at AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020. (Dr. Tawagi)
Breast Cancer and COVID-19: Impact of Active Treatment on Severe Outcomes accepted for poster presentation at the 2020 San Antonio Breast Cancer Symposium®, December 8-12, 2020. (Dr. Tawagi)
Lunski, Michael J., Jeffrey Burton, Karine Tawagi, Diana Maslov, Victoria Simenson, Daniel Barr, Helen Yuan et al. "Multivariate mortality analyses in COVID‐19: Comparing patients with cancer and patients without cancer in Louisiana." Cancer (2020). PMID #33112411
Maslov, Diana, Karine Tawagi et al. “Timing of Steroid Initiation and Response Rates to Immune Checkpoint Inhibitors in Metastatic Cancer". Submitted to JITC (2021).
Azeem Khan M, Florou V, Swami U. Immunotherapy and fatigue: what we know and what we don't know. Oncotarget. 2021;12(8):719-720. Published 2021 Apr 13. doi:10.18632/oncotarget.27946.
Boyce, Jessica, Karine Tawagi, and John T. Cole. "Primary colon adenocarcinoma with choriocarcinoma differentiation: a case report and review of the literature." Journal of Medical Case Reports 14, no. 1 (2020): 1-10. PMID #33190644
“Real-world data and racial outcomes for NSCLC in the chemo-immunotherapy era” (Dr. Markabawi) to be presented at 2021 IASLC meeting.
"PD-1/PD-L1/CTLA-4 Inhibitor therapy following progression on a differentPD-1/PD-L1 Inhibitor : a case series." (Dr. Mukamalla) Presented at 2020 SITC.
Clinical outcomes for advanced hepatocellular carcinoma patients treated with systemic agents in real-world practice, first author, poster presentation' (Dr. Tawagi) Presented at 2020 NCCN conference.
Clinical characteristics and outcomes of patients with resectable, metastatic colorectal cancer treated with adjuvant FOLFIRI after progression on neoadjuvant FOLFOX ASCRS Accepted January 24, 2020. (Dr. Luk)
Malignant Mesothelioma and Germline Heterozygous BAP1 Mutation in a Young Woman Presenting with Recurrent Pleural Effusions and Worsening Pneumothorax After Talk Pleurodesis. Accepted CHEST 2020. (Dr. Luk)
Utilization of genomic mutational information in breast cancer patients. (Dr. Gadde)
Interest in adaptive immunotherapies, and immune-related toxicities in solid tumors. (Dr Tawagi)
Involvement in prospective clinical trial looking using regimen to augment standard immunotherapy in melanoma & genitourinary patients. (Dr. Tawagi)
Retrospective study looking at rate of autoimmune flares & irAES in patients with a pre-existing history of autoimmune disease. (Dr. Tawagi)
Abstract Accepted Dr. Tawagi: Timing of steroid doses and response rates to immune-checkpoint inhibitors in metastatic cancer. SITC 35th Anniversary Annual Meeting during SITC 2020, Virtual Poster Hall, 11/11/2020 – 11/14/2020 9a-5p. Abstract ID 247
Abstract Accepted Dr. Mukkamala: PD-1/PD-L1/CTLA-4 inhibitor therapy following progression on a different PD-1/PD-L1 inhibitor: a case series. SITC 35th Anniversary Annual Meeting during SITC 2020, Virtual Poster Hall, 11/11/2020 – 11/14/2020 9a-5p
JMCR-D-20-00712R1 - Primary colon adenocarcinoma with choriocarcinoma differentiation: a case report and review of literature Jessica Boyce, MD; Karine Tawagi, MD; John T Cole, MD - Journal of Medical Case Reports - Accepted for Publication (9/29/20)
The changing molecular landscape of AML and its impact on treatment. Review Article Integr Mol Med 2020 doi: 10.15761/IMM.1000405. June 30, 2020. Dr. Lunski and Dr. Khan with Drs. Finn, Davis, Staton and Badari.